Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...

Current treatments are estimated to only reduce about one-third of the disease burden of depressive disorders. Prevention may be an alternative strategy to further reduce the disease burden of ...

Major depressive disorder ... remit following adequate antidepressant treatment, while most MDD patients suffer from significant core depressive or residual symptoms during their clinical course.

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at a Compound Annual Growth Rate (CAGR) of 2.8%, reaching a market size of USD ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

PharmacoEconomics: “Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.” GoodTherapy ...

Columnist Brianna Albers discovered a common tool for video game accessibility was missing in a long-awaited "Dragon Age" release.

its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the Company's ...

Feeling tired and unmotivated, sleeping more hours, and moving at a slower pace are possible signs that you’re exiting a manic episode ... re receiving medical treatment for bipolar disorder ...

SAD has a seasonal pattern, with recurring episodes happening more predictably during certain seasons - most commonly during ...

This connection remains controversial, particularly in individuals with major depressive disorder (MDD). They divided 1,718 first-episode patients with drug-naïve MDD into TSH abnormal (TSH-AB) and ...